HD-OPM Archive
Topics › Inflammation & CRP

Empagliflozin reduced monocyte-platelet aggregates, hinting at vascular anti-inflammation

Louis Nervegna · Oct 23, 2026 · ♥ 4 reactions · 0 comments · original Facebook post
Inflammation & CRPInsulin resistance & diabetes
AI summary & key facts

A Circulation pilot study led by Vanderbilt found participants treated with the SGLT2 inhibitor empagliflozin had reduced monocyte-platelet aggregates, clusters of immune cells and platelets linked to cardiovascular damage. It suggests diabetes drugs may also reduce vascular inflammation, though this is a small pilot.

Link to journal paper:

Paper · Circulation · 2026SGLT2 Inhibitor Empagliflozin Reduces Circulating Monocyte-Platelet Aggregates: A Pilot Studyahajournals.org

#sglt2HD #empagliflozinHD #inflammationHD

Research cited

A Diabetes Drug May Also Help Reduce Vascular Inflammation 🧬❤️

Could diabetes medications do more than control blood sugar? New research published in Circulation suggests that empagliflozin, an SGLT2 inhibitor, may also influence inflammatory processes linked to cardiovascular damage.

🔬 What did researchers discover?

A clinical trial led by Vanderbilt Health researchers found that participants treated with empagliflozin experienced a reduction in monocyte-platelet aggregates clusters of immune cells and platelets associated with inflammation and blood vessel damage.

📊 Why is this important?

The reduction was measurable after just two weeks of treatment, suggesting that SGLT2 inhibitors may influence cellular immune activity relatively quickly. These findings could help researchers better understand how this class of medication may contribute to cardiovascular and kidney protection.

🩺 What comes next?

Although the results offer promising insights into the anti-inflammatory effects of empagliflozin, further research is needed to establish how these cellular changes relate to long-term clinical outcomes. The findings do not mean the medication should be used solely to treat inflammation.

The takeaway: Diabetes medications may have benefits beyond blood sugar management, and understanding their effects on immune cells could open new directions for cardiovascular research.

Source: Mashayekhi, M., et al. (2026). SGLT2 inhibitors reduce inflammatory monocyte-platelet aggregates in humans. Circulation.

#DiabetesResearch #Empagliflozin #HeartHealth #Inflammation #MedicalResearch

May be an image of text
← newer: After Keto-CTA reanalysis, plaque growth still matches untreolder: Which statin to choose: atorvastatin, rosuvastatin and other →